734. Efficacy of sulbactam-durlobactam (SUL-DUR) versus colistin in patients with extensively drug-resistant (XDR) and pan-drug resistant (PDR) Acinetobacter baumannii-calcoaceticus complex (ABC) infections

医学 粘菌素 内科学 鲍曼不动杆菌 菌血症 亚胺培南 舒巴坦钠 抗药性 碳青霉烯 肺炎 抗生素 抗生素耐药性 铜绿假单胞菌 微生物学 细菌 生物 遗传学
作者
Alita A. Miller,Sarah M. McLeod,Adam B. Shapiro,Khurram Z. Rana,Drew E. Lewis,Gabrielle Poirier,Daria Chabas,David Altarac
出处
期刊:Open Forum Infectious Diseases [Oxford University Press]
卷期号:9 (Supplement_2) 被引量:1
标识
DOI:10.1093/ofid/ofac492.025
摘要

Abstract Background Acinetobacter baumannii-calcoaceticus complex (ABC) is a group of closely related species that cause serious infections associated with substantial mortality due in large part to very high antibiotic resistance rates and, consequently, a lack of effective therapies (Lancet 2022: 399;629–655). ATTACK was a global, active-controlled Phase 3 trial conducted to evaluate the efficacy and safety of SUL-DUR versus colistin (COL) for patients with ABC infections. Clinical and microbiological outcomes of all CRABC m-MITT patients vs. those with XDR or PDR ABC infections in ATTACK. Methods Part A was a blinded, randomized, non-inferiority study in ABC pneumonia or bacteremia. In Part B, patients who did not tolerate COL or had COL-resistant (R) ABC infections received SUL-DUR. All patients received imipenem/cilastatin as background therapy. Primary endpoint included 28-day all-cause mortality in Part A patients with carbapenem-resistant ABC at baseline (CRABC m-MITT). Clinical and microbiological outcomes were evaluated at End of Therapy (EOT), Test of Cure (TOC) and late follow-up (LFU) visits. COL-R was defined as MIC ≥ 4 µg/ml. MDR and XDR were defined according to Magiorakis et al (2012) CMI: 18, 268–81; PDR was defined as non-susceptibility to all approved agents (7 antibiotic classes) tested. Results Of 149 baseline ABC isolates from CRABC m-MITT patients, 100% were (MDR), 129 (87%) were XDR and 14 (9.4%) were PDR. 19 (15%) of XDR and 10 (71%) of PDR ABC infections were in patients with bacteremia. 51% of XDR (N = 66) and all PDR ABC infections were in European patients. The SUL-DUR MIC50/90 against the XDR set was 2/4 µg/ml (range = 0.25 – 8 µg/ml). 13 (93%) PDR ABC were susceptible to SUL-DUR at ≤ 4 µg/mL, its preliminary breakpoint. Clinical and microbiological outcomes favoring SUL-DUR over COL were nearly identical in patients with XDR ABC infections as in the total population (Table 1). Of the 13 evaluable patients with PDR ABC infections treated with SUL-DUR in Part B, only one (7.7%) did not survive to Day 28 and 12 (92%) experienced clinical and microbiological cure at TOC. Conclusion Patients enrolled in ATTACK had very high rates of XDR and PDR ABC infections, consistent with emerging global trends. Patients treated with SUL-DUR experienced better clinical and microbiological outcomes than those treated with COL, including those infected with XDR and PDR ABC. Disclosures Alita Miller, PhD, Entasis Therapeutics: Employee Sarah McLeod, PhD, Entasis Therapeutics: Employee Adam B. Shapiro, Ph.D, Entasis Therapeutics: Employee|Entasis Therapeutics: Stocks/Bonds Khurram Rana, PharmD, Entasis Therapeutics: Employee|Entasis Therapeutics: Ownership Interest|Entasis Therapeutics: Stocks/Bonds Drew Lewis, MD, MTM&H, Entasis Therapeutics: employee|Entasis Therapeutics: employee|Entasis Therapeutics: Stocks/Bonds|Entasis Therapeutics: Stocks/Bonds Gabrielle Poirier, BS, Entasis Therapeutics: Ownership Interest|Entasis Therapeutics: Stocks/Bonds Daria Chabas, BS, Entasis Therapeutics: Ownership Interest|Entasis Therapeutics: Stocks/Bonds David Altarac, MD, MPA, Entasis Therapeutics: Ownership Interest|Entasis Therapeutics: Stocks/Bonds.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
本本完成签到 ,获得积分10
刚刚
复杂的师完成签到,获得积分10
1秒前
Eiffel发布了新的文献求助20
1秒前
Moon发布了新的文献求助10
1秒前
唐飒发布了新的文献求助10
1秒前
Lisiqi完成签到,获得积分10
1秒前
wanci的应助被HU采纳,获得10
1秒前
mu完成签到,获得积分10
1秒前
1秒前
1秒前
SciGPT的应助被正直的语海采纳,获得10
2秒前
打打的应助被聪明的梦梦采纳,获得10
2秒前
独特翠芙完成签到 ,获得积分10
3秒前
fff完成签到,获得积分10
3秒前
桐桐的应助被优雅33采纳,获得30
3秒前
3秒前
3秒前
Ava的应助被打酱油的清华苗子采纳,获得10
4秒前
康康给康康的求助进行了留言
4秒前
4秒前
4秒前
虚幻的书南完成签到,获得积分10
5秒前
背后老太完成签到,获得积分10
5秒前
深情安青的应助被优雅阳采纳,获得10
5秒前
Owen的应助被33采纳,获得10
5秒前
李爱国的应助被温暖砖头采纳,获得10
6秒前
老老熊发布了新的文献求助10
6秒前
6秒前
研友_LwlAgn完成签到,获得积分10
6秒前
清秀的远望完成签到,获得积分10
6秒前
supman完成签到,获得积分10
6秒前
唐飒完成签到,获得积分10
6秒前
Charlie发布了新的文献求助10
7秒前
xushanfeng完成签到,获得积分10
7秒前
坚定的无心完成签到,获得积分10
7秒前
cz完成签到 ,获得积分10
7秒前
11完成签到 ,获得积分10
7秒前
眼睛大的新之完成签到,获得积分10
8秒前
coconut完成签到,获得积分10
8秒前
llopcop完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173804
求助须知:如何正确求助?哪些是违规求助? 9565979
关于积分的说明 21783694
捐赠科研通 7767997
什么是DOI,文献DOI怎么找? 3431629
关于科研通互助平台的介绍 2555879
邀请新用户注册赠送积分活动 2476919